The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTCCL Archive

NCI CTEP-Approved Trials for the Month of February

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Phase II

GOG-0283: A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND# 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression. Gynecologic Oncology Group; Hyman, David Michael. (212) 639-2000

Phase III

E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765) Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL). Eastern Cooperative Oncology Group; Shanafelt, Tait D. 507-284-2358

Other Phases

AAML13B7-Q: Prognostic Significance of MMRN1 in Pediatric Acute Myeloid Leukemia (AML). Children’s Oncology Group; Walter, Roland Bruno. (206) 667-3599

AAML13B8-Q: Global Proteomic and Phosphoproteomic Profiling of Normal B Cells Isolated from COG AAML1031 Study Patients in AML Remission. Children’s Oncology Group; Pandey, Akhilesh. (410) 502-6662

ANBL13B9-Q: 3D Nuclear Telomere Organization in Neuroblastoma. Children’s Oncology Group; Mai, Sabine. (204) 787-2135

ANBL13B10-Q: The Role of FGFR4 in Neuroblastoma Pathogenesis. Children’s Oncology Group; Zage, Peter Eric. (832) 824-4615

AREN13B2-Q: Characterization of the Chromosome 11p15 Imprinting Regulation by Epigenetic and Transcriptomic Analyses in Wilms Tumor Patients. Children’s Oncology Group; Michels, Karin B. (617) 732-4895

YOU MAY BE INTERESTED IN

Capitol Hill

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die”

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.
By Claire Marie Porter
Guest Editorial

Building cancer care resilience through international observerships: Lessons from Ukraine

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

By Nataliya Kovalchuk, Andriy Beznosenko, Vitaliy Y. Poylin, Rostyslav Semikov, Arman Kacharian, Douglas Davis, Nataliya Uboha, Natalka Suchowerska, Viktor Iakovenko, Jacqueline Hart, Mark Poznansky, Darya Kizub and Nelya Melnitchouk
ClinicalTrials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account